search
Back to results

Evaluation of the Implantation of the End-vascular Creation of the Arteriovenous Fistulas in Patients in the University Hospital of Araba. Pilot Study.

Primary Purpose

Efficacy and Safety

Status
Recruiting
Phase
Not Applicable
Locations
Spain
Study Type
Interventional
Intervention
endoFAVI
Sponsored by
Fernando López Zárraga
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional supportive care trial for Efficacy and Safety

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Adult (older than 18).
  • Currently be receiving chronic dialysis, or be waiting to start the chronic dialysis in the next six months.
  • Have veins with diameter >= 2.0mm to the creation of the fistula, established by Duplex ultrasound or venogram.
  • Have arteries with diameter >= 2.0mm to the creation of the fistula, established by Duplex ultrasound or venogram.
  • Cubital and radial arterial flow for the hand, confirmed with Duplex Ultrasound and/or Allen test.
  • Dismissed the realization of cephalic-radius FAVI for surgical technical problems.
  • Informed Consent to participate in the study.

Exclusion Criteria:

  • Known central venous stenosis or narrowing of the central vein > 50% according to images on the same side as the creation of the planned FAV.
  • Absence of perforator that feed the target cannulation, by venogram.
  • Occlusion or stenosis > 50% of the cephalic basilica vein of the target cannulation.
  • Cannulation target vein of less than 2.0 mm of diameter.
  • Significantly compromised flow (>= 50% of stenosis) in the treatment arm as determined by the doctor and the images.
  • Ejection fraction documented <= 35% in the last 6 months.
  • Pregnant women.
  • Heart failure Class III or IV of the New York Heart Association (NYHA).
  • Hypercouagulability status demonstrated ( Antiphospholipid Syndrome, Leiden factor V, Protein deficit S, ...).
  • Known hemorrhagic diathesis.
  • Documented history of drug abuse including intravenous drugs within six months of FAV creation.
  • Concomitant major surgical procedure "planned" within three months of recruitment or major previous surgery within 30 days of recruitment.
  • Known iodine contrast allergy that cannot be properly premedicated.
  • Known adverse effects for sedation and/or anesthesia that cannot be properly premedicated.
  • Evidence of active infections on the day of the index procedure.
  • Life expectancy < 1 year.
  • The patient is not willing to provide an written informed consent, is not geographically stable and/or is not willing to cmply with the required follow-up.
  • Patient with an objective cannulation vein of more than 6 mm of deep that would require a transposition procedure, defined as the elevation of an objective cannulation vein nad the creation of a new fistula AV.
  • The patient is nit willing to undergo of second stage, defined as a conversion to surgical FAVI, central catheter arrangement, thrombectomy/rescue fibrinolysis, stenoic area angioplasty, ...

Sites / Locations

  • Araba University Hospital (SantiagoRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

Intervention group

Control group

Arm Description

Outcomes

Primary Outcome Measures

Percentage of endoFAVI physiologically appropriate for the hemodialysis during the next three months to the creation.
The absence of stenosis and thrombosis of the fistula and the racial artery flow >=500 mL/min and the vein diameter >= 5 mm measured by duplex ultrasonography, or successful administration of hemodialysis with 2 needles with flow >= 350 mL/min.

Secondary Outcome Measures

Full Information

First Posted
December 11, 2019
Last Updated
March 11, 2022
Sponsor
Fernando López Zárraga
search

1. Study Identification

Unique Protocol Identification Number
NCT04197544
Brief Title
Evaluation of the Implantation of the End-vascular Creation of the Arteriovenous Fistulas in Patients in the University Hospital of Araba. Pilot Study.
Official Title
Evaluation of the Implantation of the End-vascular Creation of the Arteriovenous Fistulas in Patients in the University Hospital of Araba. Pilot Study.
Study Type
Interventional

2. Study Status

Record Verification Date
March 2022
Overall Recruitment Status
Recruiting
Study Start Date
July 28, 2021 (Actual)
Primary Completion Date
November 1, 2022 (Anticipated)
Study Completion Date
January 31, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Fernando López Zárraga

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
In last few years, there is a new technology that permits the endovascular fistula creation with a minimum vascular trauma and the first results show encouraging results with high technical success rate, low resurgent and failure rates and good usability for hemodialysis. The implementation of the endoFAVI realization in dialysis patients is an emergent procedure that in our hospital can contribute important benefits to the patients, savings to the health system, as well research and innovation in the implicate services.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Efficacy and Safety

7. Study Design

Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
14 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Intervention group
Arm Type
Experimental
Arm Title
Control group
Arm Type
No Intervention
Intervention Type
Procedure
Intervention Name(s)
endoFAVI
Intervention Description
EndoFAVI creation to patients that require vascular access for hemodialysis.
Primary Outcome Measure Information:
Title
Percentage of endoFAVI physiologically appropriate for the hemodialysis during the next three months to the creation.
Description
The absence of stenosis and thrombosis of the fistula and the racial artery flow >=500 mL/min and the vein diameter >= 5 mm measured by duplex ultrasonography, or successful administration of hemodialysis with 2 needles with flow >= 350 mL/min.
Time Frame
Three months next the creation

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Adult (older than 18). Currently be receiving chronic dialysis, or be waiting to start the chronic dialysis in the next six months. Have veins with diameter >= 2.0mm to the creation of the fistula, established by Duplex ultrasound or venogram. Have arteries with diameter >= 2.0mm to the creation of the fistula, established by Duplex ultrasound or venogram. Cubital and radial arterial flow for the hand, confirmed with Duplex Ultrasound and/or Allen test. Dismissed the realization of cephalic-radius FAVI for surgical technical problems. Informed Consent to participate in the study. Exclusion Criteria: Known central venous stenosis or narrowing of the central vein > 50% according to images on the same side as the creation of the planned FAV. Absence of perforator that feed the target cannulation, by venogram. Occlusion or stenosis > 50% of the cephalic basilica vein of the target cannulation. Cannulation target vein of less than 2.0 mm of diameter. Significantly compromised flow (>= 50% of stenosis) in the treatment arm as determined by the doctor and the images. Ejection fraction documented <= 35% in the last 6 months. Pregnant women. Heart failure Class III or IV of the New York Heart Association (NYHA). Hypercouagulability status demonstrated ( Antiphospholipid Syndrome, Leiden factor V, Protein deficit S, ...). Known hemorrhagic diathesis. Documented history of drug abuse including intravenous drugs within six months of FAV creation. Concomitant major surgical procedure "planned" within three months of recruitment or major previous surgery within 30 days of recruitment. Known iodine contrast allergy that cannot be properly premedicated. Known adverse effects for sedation and/or anesthesia that cannot be properly premedicated. Evidence of active infections on the day of the index procedure. Life expectancy < 1 year. The patient is not willing to provide an written informed consent, is not geographically stable and/or is not willing to cmply with the required follow-up. Patient with an objective cannulation vein of more than 6 mm of deep that would require a transposition procedure, defined as the elevation of an objective cannulation vein nad the creation of a new fistula AV. The patient is nit willing to undergo of second stage, defined as a conversion to surgical FAVI, central catheter arrangement, thrombectomy/rescue fibrinolysis, stenoic area angioplasty, ...
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Fernando López Zárraga, Dr
Phone
0034 945007600
Email
FERNANDO.LOPEZZARRAGA@osakidetza.eus
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Fernando López Zárraga, Dr
Organizational Affiliation
Basque health System
Official's Role
Principal Investigator
Facility Information:
Facility Name
Araba University Hospital (Santiago
City
Vitoria-Gasteiz
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Fernando López Zárraga, Dr.
Phone
0034 945 007600

12. IPD Sharing Statement

Learn more about this trial

Evaluation of the Implantation of the End-vascular Creation of the Arteriovenous Fistulas in Patients in the University Hospital of Araba. Pilot Study.

We'll reach out to this number within 24 hrs